Horowitz, Neil
Dana-Farber Cancer Institute
13 papers on CoChatORCID 0000-0002-4854-0642
Most cited papers
- Verified
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 3,725
- Verified
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 3,201
- Verified
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 2,546
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 2,256
- Verified
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell
Cancer Cells and MetastasisPluripotent Stem Cells Research
Cited by 2,180
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 552
- Verified
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports
Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research
Cited by 500
- Verified
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment
Cited by 452
- Verified
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems
Cancer Genomics and DiagnosticsCancer-related Molecular Pathways
Cited by 431
- Verified
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 399
- Verified
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell
Cell death mechanisms and regulationCancer-related Molecular Pathways
Cited by 378
- Verified
The fallopian tube, “precursor escape” and narrowing the knowledge gap to the origins of high-grade serous carcinoma
Soong, T. R., Howitt, B. E., Horowitz, N., Nucci, M. R., & Crum, C. P. (2019) · Gynecologic Oncology
Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer
Cited by 110
- Verified
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Krasner, C. N., Campos, S. M., Young, C. L., Chadda, K. R., Lee, H., Birrer, M. J., Horowitz, N. S., Konstantinopoulos, P. A., D'Ascanio, A. M., Matulonis, U. A., et al. (2021) · Gynecologic Oncology
Ovarian cancer diagnosis and treatmentCancer therapeutics and mechanisms
Cited by 42
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free